Status:
RECRUITING
CCCG-ALCL-2020 for Chinese Children and Adolescents with Newly Diagnosed High-risk ALCL
Lead Sponsor:
Children's Cancer Group, China
Collaborating Sponsors:
Shanghai Children's Medical Center
Nanjing Children's Hospital
Conditions:
Pediatric Anaplastic Large Cell Lymphoma
Eligibility:
All Genders
Up to 18 years
Phase:
PHASE3
Brief Summary
A prospective study on the efficacy of modified ALCL99 regimens in the treatment of the current Chinese pediatric and adolescent high-risk ALCL and compared with our historical data.
Detailed Description
Anaplastic large cell lymphoma (ALCL) accounts for 15% of pediatric and adolescent non-Hodgkin lymphomas (NHLs). In our historical study (retrospective multicenter study), the 3-year event-free surviv...
Eligibility Criteria
Inclusion
- Patient must be ≤ 18 years at the time of diagnosis
- Newly diagnosed patients with histologically confirmed high-risk anaplastic large cell lymphoma
- No congenital immunodeficiency, HIV infection, or prior organ transplant
Exclusion
- Patients have received prior cytotoxic chemotherapy/target therapy/radiation, if any steroid applied, total prior steroids dosage \> Dexamethasone 40 mg/m2 for the current diagnosis or any cancer
- Patients have overwhelming infection, and a life expectancy of \< 2 weeks
Key Trial Info
Start Date :
March 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2029
Estimated Enrollment :
172 Patients enrolled
Trial Details
Trial ID
NCT04881838
Start Date
March 1 2021
End Date
March 1 2029
Last Update
February 13 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Children's Medical Center
Shanghai, China